Ironwood Pharmaceuticals, Inc. (IRWD) - Not Halal (Non-Compliant)
Ironwood Pharmaceuticals, Inc. (IRWD) is classified as Not Halal (Non-Compliant) according to AAOIFI Shariah screening standards. This assessment is based on business activity screening and financial ratio analysis using the AAOIFI methodology.
Business Activity Screen
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Result
- Pass
- Reason
- The sector "Healthcare" and industry "Drug Manufacturers - Specialty & Generic" are not in the excluded categories.
Financial Ratios
- Debt Ratio
- Value: 71.3% | Threshold: 30% | Result: Fail
- Cash & Interest-bearing Securities Ratio
- Value: 14.2% | Threshold: 30% | Result: Pass
- Non-Permissible Income Ratio
- Value: 1.4% | Threshold: 5% | Result: Pass
Dividend Purification
Purification percentage: 1.38%.Based on the company's financial statements, approximately 1.38% of dividend income should be donated to charity for purification. This is derived from identified interest income (1.38% of total income). Some scholars may differ on the exact calculation method.
About Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support, as well as for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.